和铂医药-B(02142)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02142 和铂医药-B

开市前 07-27 09:13:51

12.510

+0.000

0.00%

最高12.510	最低12.510	成交量42.30万
今开12.510	昨收12.510	日振幅0.00%
总市值108.59亿	流通市值108.59亿	总股本8.68亿
成交额526.68万	换手率0.05%	流通股本8.68亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02142","market":"HK","secType":"STK","nameCN":"和铂医药-B","latestPrice":12.51,"timestamp":1785114300131,"preClose":12.51,"halted":0,"volume":423000,"delay":0,"changeRate":0,"floatShares":868000000,"shares":868000000,"eps":0.8626368455723205,"marketStatus":"开市前","change":0,"latestTime":"07-27 09:13:51","open":12.51,"high":12.51,"low":12.51,"amount":5266799.7,"amplitude":0,"askPrice":12.99,"askSize":13000,"bidPrice":12.33,"bidSize":10000,"shortable":3,"etf":0,"ttmEps":0.8626290034191788,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1785115800000},"marketStatusCode":1,"adr":0,"listingDate":1607529600000,"exchange":"SEHK","adjPreClose":12.51,"openAndCloseTimeList":[[1785115800000,1785124800000],[1785128400000,1785139200000]],"volumeRatio":0,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02142","defaultTab":"news","newsList":[{"id":"2653705587","title":"港股异动 | 和铂医药-B(02142.HK)盈喜后涨超4% 预计中期溢利约6200万美元至约6700万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2653705587","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653705587?lang=zh_cn&edition=full","pubTime":"2026-07-24 09:33","pubTimestamp":1784856788,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","BK1583","02142","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112421585","title":"和铂医药-B披露正面盈利预告：上半年收入最高1.25亿美元，预计实现盈利","url":"https://stock-news.laohu8.com/highlight/detail?id=1112421585","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1112421585?lang=zh_cn&edition=full","pubTime":"2026-07-24 08:06","pubTimestamp":1784851570,"startTime":"0","endTime":"0","summary":"2026年7月24日，和铂医药-B发布正面盈利预告称，根据截至2026年6月30日止六个月的初步未审计管理账目，预计期内收入介乎约1.2亿美元至1.25亿美元，较2025年同期1.01亿美元显著增长。公司同时预期，上半年溢利将在约62百万美元至67百万美元之间；经调整溢利总额预计为70百万美元至75百万美元。和铂医药-B表示，以上财务数据尚未经过董事会旗下审核委员会或公司核数师的审阅，最终业绩将于2026年8月底发布的中期业绩公告中披露。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653772889","title":"和铂医药-B(02142)发盈喜 预计中期溢利约6200万美元至约6700万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2653772889","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653772889?lang=zh_cn&edition=full","pubTime":"2026-07-24 08:05","pubTimestamp":1784851541,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和铂医药-B 发布公告，预期截至2026年6月30日止六个月的收入介乎约1.2亿美元至约1.25亿美元，而截至2025年6月30日止六个月的收入则为约1.01亿美元。预期截至2026年6月30日止六个月的溢利介乎约6200万美元至约6700万美元。预期经调整溢利总额介乎7000万美元至7500万美元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1471717.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1574","02142","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653772662","title":"和铂医药发布2026年中期盈利预喜：实现连续七个半年度盈利，平台型药企优势助力业绩可持续增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2653772662","media":"美通社","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653772662?lang=zh_cn&edition=full","pubTime":"2026-07-24 08:02","pubTimestamp":1784851320,"startTime":"0","endTime":"0","summary":"中国上海，美国马萨诸塞州剑桥和荷兰鹿特丹2026年7月24日 /美通社/ -- 和铂医药，一家专注于免疫性疾病、肿瘤及其他领域创新抗体疗法发现及开发的全球生物医药公司，今日发布截至2026年6月30日的中期业绩盈利预喜。和铂医药实现连续七个半年度盈利，标志着公司正式跨入\"常态化盈利\"阶段，进一步验证了平台型制药集团商业模式的可持续性和可复制性。报告期内，公司多项重磅合作贡献显著收入。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"prnasia","url":"http://wwwold.prnasia.com/story/archive/5010897_ZH10897_1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/5010897_ZH10897_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK1583","02142","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130107379","title":"和铂医药与维也纳医科大学达成研究合作，共同推进感染性疾病全人源抗体开发","url":"https://stock-news.laohu8.com/highlight/detail?id=1130107379","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1130107379?lang=zh_cn&edition=full","pubTime":"2026-07-23 08:56","pubTimestamp":1784768173,"startTime":"0","endTime":"0","summary":"和铂医药宣布，已与维也纳医科大学建立研究合作关系，双方将携手推进针对感染性疾病的全人源抗体开发项目。此项合作旨在利用和铂医药的专有技术平台与维也纳医科大学的学术研究专长，加速创新疗法的发现与转化。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","BK1161","02142","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652036024","title":"港股异动 | 和铂医药-B(02142.HK)盘中跌超10% 辉瑞宣布终止和铂ADC药物SGN-MesoC2全部研发","url":"https://stock-news.laohu8.com/highlight/detail?id=2652036024","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652036024?lang=zh_cn&edition=full","pubTime":"2026-07-17 15:53","pubTimestamp":1784274820,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","02142","BK1583","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651145145","title":"和铂医药-B(02142)：HBM7575用于治疗哮喘的新药临床试验申请获NMPA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2651145145","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651145145?lang=zh_cn&edition=full","pubTime":"2026-07-15 18:02","pubTimestamp":1784109738,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和铂医药-B(02142)公布，靶向胸腺基质淋巴细胞生成素(TSLP)及一个未公开靶点的长效双特异性抗体HBM7575(亦称SKB575)的新药临床试验(IND)申请已获中国国家药品监督管理局(NMPA)批准，用于治疗哮喘。该款双特异性抗体由公司与四川科伦博泰生物医药股份有限公司(科伦博泰) (06990)合作研发。此前，HBM7575/SKB575用于治疗特应性皮炎的I期临床研究已顺利完成首例受试者给药。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1467931.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BMED","BK1574","IBBQ","BK1583","BK1161","02142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651991128","title":"【券商聚焦】中信证券：新基药目录有望加速创新药基层落地","url":"https://stock-news.laohu8.com/highlight/detail?id=2651991128","media":"金吾财讯","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651991128?lang=zh_cn&edition=full","pubTime":"2026-07-14 08:57","pubTimestamp":1783990650,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信证券研究指，《2026年版国家基本药物目录》于7月9日正式发布，将于9月1日起实施。该机构认为，本次新版基药目录新增药物均已属于医保药品，随着基药与医保的深度协同联动，有望极大加速创新药的基层落地，医保控费与创新回报形成良性循环。","market":"us","thumbnail":"https://static.szfiu.com/news/20250106/ZGNkM2E3NDVjMTk0N2Q5ZDk4NjYxNjc1YjA4NjMzOTA5MjkwMDE=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/ZGNkM2E3NDVjMTk0N2Q5ZDk4NjYxNjc1YjA4NjMzOTA5MjkwMDE=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1985769","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0051755006.USD","IBBQ","IE0008368742.USD","LU1328277881.USD","01093","LU1226288253.USD","LU0359201612.USD","LU1152091168.USD","SG9999002463.SGD","LU0823426480.USD","BK1610","LU1226287792.SGD","02616","LU2039709279.SGD","01177","01801","LU1961090484.USD","LU0314109678.HKD","02269","LU2476274720.SGD","LU0043850808.USD","01877","LU2488822045.USD","09926","LU2328871848.SGD","600030","LU0588546209.SGD","LU0405327494.USD","09688","HK0000165453.HKD","LU0979878070.USD","LU1960683339.HKD","KURE","09995","BK1500","159992","KCE","06978","02142","LU1242518931.SGD","06185","IE00BPRC5H50.USD","LU0327786744.USD","LU0417516902.SGD","LU0572944931.SGD","06030","MEDX","06160","BK1161","LU1997244956.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651568164","title":"【券商聚焦】中信建投：创新药企仍是高增长主线、BD交易持续催化业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=2651568164","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651568164?lang=zh_cn&edition=full","pubTime":"2026-07-13 08:53","pubTimestamp":1783903985,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投证券研究指出，1）制药产业链：创新药企仍是高增长主线，BD交易持续催化业绩。BD授权收入成为多家公司中期业绩关键变量。上游供应链受益于国产替代及下游需求恢复，Q2增速普遍提升，利润端弹性显著。建议关注Q2高增长公司的配置机会。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250109/NWI3NDNkNGUxZmM1MTMzOTE0MzEwMTk=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/NWI3NDNkNGUxZmM1MTMzOTE0MzEwMTk=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1985645","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0348784397.USD","MEDX","LU1993786604.SGD","06978","LU2242644610.SGD","LU1969619763.USD","IE0008368742.USD","LU1226288170.HKD","BD","LU0348735423.USD","BK1588","LU0455707207.USD","01093","02142","LU0456846285.SGD","LU1688375341.USD","LU1813983027.USD","01877","02616","09995","BK1515","LU0067412154.USD","09926","LU0501845795.SGD","LU0359201612.USD","LU0516422366.SGD","06160","LU2097828474.EUR","IBBQ","LU2097828631.EUR","IE00B0JY6N72.USD","09688","159992","KCE","LU1960683339.HKD","06185","01801","LU1961090484.USD","LU2488822045.USD","LU0051755006.USD","601066","KURE","01177","LU1807302812.USD","02269","BK1161","IE0008369823.USD","LU0348825331.USD","IE00B5MMRT66.SGD","LU0359202008.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112036125","title":"和铂医药-B更新2026年6月股份变动月报表，股本小幅增长","url":"https://stock-news.laohu8.com/highlight/detail?id=1112036125","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1112036125?lang=zh_cn&edition=full","pubTime":"2026-07-07 16:46","pubTimestamp":1783414002,"startTime":"0","endTime":"0","summary":"和铂医药控股有限公司于2026年7月7日公布了截至2026年6月30日的股份变动月报表。报告期内，公司法定/注册股本与上月保持一致，注册股本总额为USD 500,000，未见变动。本月末，公司已发行股份总数小幅增长，公众持股量符合香港联交所相关要求。公司在公告中声明已遵守香港联交所《上市规则》及相关法律规定，所有有关本期股份发行及转让事项均已获董事会授权批准。公告由执行董事王劲松签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648634520","title":"【券商聚焦】中信建投：看好相关创新药及制药企业医保准入与商保增量空间","url":"https://stock-news.laohu8.com/highlight/detail?id=2648634520","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648634520?lang=zh_cn&edition=full","pubTime":"2026-07-03 08:36","pubTimestamp":1783038993,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投研究指，2026年6月29日，国家医保局公示通过2026年基本医保目录及商保创新药目录调整初步形式审查的药品名单及相关信息。叠加今年首次引入的“预申报”机制，本次结果充分体现了医保目录调整对创新药的持续倾斜，看好相关创新药及制药企业的医保准入与商保增量空间。","market":"nz","thumbnail":"https://static.szfiu.com/news/20241108/MDc2YjQxZmY4Y2VkNWEzNDU4MmJiNGExMDgxOTA3MjUwMzc=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MDc2YjQxZmY4Y2VkNWEzNDU4MmJiNGExMDgxOTA3MjUwMzc=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1985028","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2476274720.SGD","01093","LU1242518931.SGD","02269","159992","06160","LU1688375341.USD","LU2488822045.USD","LU0043850808.USD","LU0456846285.SGD","LU1226287875.USD","LU3063872942.SGD","06978","LU1961090484.USD","01177","LU0067412154.USD","LU0516422366.SGD","LU0856984785.SGD","LU2778985437.USD","09926","LU0348766576.USD","LU2097828805.USD","09688","601066","LU0072913022.USD","LU1969619763.USD","IE0008369823.USD","01877","LU0502904849.HKD","06185","02142","HK0000165453.HKD","LU0315179316.USD","09995","BK1589","LU0501845795.SGD","LU1226287792.SGD","LU2097828631.EUR","01801","IE00B5MMRT66.SGD","02616","LU0417516738.SGD","SG9999004220.SGD","LU0417516902.SGD","01477","LU2039709279.SGD","LU2476274308.USD","LU2097828714.EUR","IE00B031HY20.USD","LU0979878070.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146509604","title":"和铂医药与龙沙达成战略合作 共同开发中枢神经系统疾病领域顶尖单域抗体血脑屏障穿透技术","url":"https://stock-news.laohu8.com/highlight/detail?id=1146509604","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1146509604?lang=zh_cn&edition=full","pubTime":"2026-07-02 08:07","pubTimestamp":1782950842,"startTime":"0","endTime":"0","summary":"和铂医药与龙沙集团宣布建立战略合作关系，双方将携手开发用于治疗中枢神经系统疾病的、基于单域抗体的顶尖血脑屏障穿透技术。此项合作旨在结合双方在生物技术研发与生产领域的专长，共同推进创新疗法的开发进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02142","BK1574","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647453054","title":"55家公司港股通新贵即将喜迎北水流入 入通门槛或已抬升至102.67亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2647453054","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647453054?lang=zh_cn&edition=full","pubTime":"2026-07-01 10:09","pubTimestamp":1782871774,"startTime":"0","endTime":"0","summary":"核心规则：市值门槛动态调整截至2026年6月30日，港股通实际纳入门槛已升至102.67亿，剔除门槛达66.89亿。这一指标直接决定了个股在指数中的权重与港股通资格。对于不同上市时长的公司，要求有所不同：对于上市公司而言，维持日均万五左右的换手率是保住港股通资格的关键。数据截止日为每年的6月30日和12月31日，这也是上市公司\"冲关\"港股通的关键时间窗口。","market":"hk","thumbnail":"https://static.tigerbbs.com/0cf777090175126e4590c3b8afdfe41e","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/0cf777090175126e4590c3b8afdfe41e"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1461288.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["01236","02526","02670","02729","06938","03277","00412","01866","03310","01956","06675","01609","01779","03388","BK4588","02142","01440","03661","02632","06106","00863","02553","09630","01021","01672","02616","06658","02272","01286","00340","07688","09637","02726","06872","01879","06636","BK4585","01651","03355","01133","01191","02335","02723","01392","01081","00068","02672","07630","00100","00600","03625","00376","03887","01511","07666","02696","06656"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2646840322","title":"【券商聚焦】中信证券：中国创新药BD交易金额超预期增长 即将进入密集数据催化期","url":"https://stock-news.laohu8.com/highlight/detail?id=2646840322","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646840322?lang=zh_cn&edition=full","pubTime":"2026-06-25 09:03","pubTimestamp":1782349398,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信证券研报指，2026年以来，中国创新药BD交易金额超预期增长，产业全球竞争力进一步提升；国内市场快速放量，从2025年报来看，头部创新药企业在新产品驱动下，创新药收入快速增长，Biopharma陆续进入盈利拐点。研报认为创新药产业全球价值凸显，接下来将进入密集数据催化期。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250109/NjdhYmE3ZDczMTc4NjgyMDYzMDA3NjI=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/NjdhYmE3ZDczMTc4NjgyMDYzMDA3NjI=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1984448","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01877","02142","IE00B031HY20.USD","SG9999002562.SGD","01801","SG9999002463.SGD","SG9999004220.SGD","06160","600030","LU2289578879.USD","01093","LU1242518857.USD","06978","IE00B0JY6N72.USD","LU0501845795.SGD","BK0196","LU0327786744.USD","09995","LU1064130708.USD","LU2097828474.EUR","BK1574","LU1997245094.SGD","BK0028","09926","IE00B5MMRT66.SGD","06185","BD","01177","LU0181495838.USD","LU0348767384.USD","LU0359202008.SGD","LU0540923850.HKD","LU0856984785.SGD","IE00BZ08YT58.USD","LU1813983027.USD","02269","LU2039709279.SGD","06030","159992","BK1610","LU1960683339.HKD","LU0405327148.USD","02616","LU1794554557.SGD","09688","LU1328277881.USD","LU0823426480.USD","LU2328871848.SGD","LU1226288253.USD","IE0008368742.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643223425","title":"和铂医药-B(02142)诉安进专利侵权胜诉获赔约2020.37万美元 最高可追偿三倍赔偿金","url":"https://stock-news.laohu8.com/highlight/detail?id=2643223425","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643223425?lang=zh_cn&edition=full","pubTime":"2026-06-15 08:32","pubTimestamp":1781483572,"startTime":"0","endTime":"0","summary":"经过2026年6月8日开始的陪审团庭审后，陪审团认定：安进侵犯了Grosveld专利，该侵权行为属于故意侵权， Grosveld专利有效，及 Harbour Antibodies有权获得约2020.37万美元的损害赔偿——即公司请求的全额赔偿。故意侵权的认定使Harbour Antibodies有权请求法院提高损害赔偿金额，可能包括最高三倍的损害赔偿。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1454159.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","BK4588","LU0122379950.USD","LU2242646821.SGD","BK1574","IE0009355771.USD","LU1057294990.SGD","LU2112291526.USD","IE00B4R5TH58.HKD","BK4533","IE00BJT1NW94.SGD","BK4566","LU2468319806.SGD","BK4581","IE00B2B36J28.USD","LU1061106388.HKD","LU2089984988.USD","IE0002141913.USD","LU0289739699.SGD","BK1161","02142","LU0320765992.SGD","LU1571399168.USD","BK4139","IE00BFTCPJ56.SGD","BK4585","SG9999001440.SGD","LU0109394709.USD","BK4534","LU1023059063.AUD","LU0889565916.HKD","LU1983299246.USD","LU0058720904.USD","LU2242652126.USD","AMGN","BK4599","IE00BJJMRZ35.SGD","LU0868494617.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191935413","title":"和铂医药-B：若全额判罚惩罚性赔偿，赔偿总额或增至约6060万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1191935413","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1191935413?lang=zh_cn&edition=full","pubTime":"2026-06-15 08:03","pubTimestamp":1781481793,"startTime":"0","endTime":"0","summary":"和铂医药-B公告指出，若法院支持并全额判罚惩罚性赔偿，此案最终裁决的总赔偿金额可能攀升至约6060万美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02142","BK1161","BK1574","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197751140","title":"和铂医药旗下Harbour Antibodies获判赔偿2020万美元 与庭审诉求全额一致","url":"https://stock-news.laohu8.com/highlight/detail?id=1197751140","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1197751140?lang=zh_cn&edition=full","pubTime":"2026-06-15 08:03","pubTimestamp":1781481793,"startTime":"0","endTime":"0","summary":"和铂医药-B宣布，其子公司Harbour Antibodies在相关诉讼中被裁定有权获得2020万美元的损害赔偿，这一金额与公司在庭审中提出的全额索赔请求完全相符。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1583","BK1161","02142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642105174","title":"港股异动 | 超长效抗TSLP抗体II期临床完成首批给药 和铂医药-B(02142)、科伦博泰生物(06990)盘中均涨超5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2642105174","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642105174?lang=zh_cn&edition=full","pubTime":"2026-06-10 13:45","pubTimestamp":1781070342,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，和铂医药-B、科伦博泰生物今日逆市走高，截至发稿，和铂医药涨3.46%，报9.86港元；科伦博泰生物涨3.82%，报402.2港元。消息面上，6月9日，科伦博泰宣布，其合作伙伴Windward Bio主导的一项II期临床研究已完成首批患者给药。据悉，SKB378/WIN378最初由科伦博泰与和铂医药共同开发，双方平分全球权益。若后续临床试验顺利推进，SKB378/WIN378有望成为首款获批上市的超长效抗TSLP抗体，用于哮喘和COPD治疗。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1452439.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","02142","06990","VXUS","BK1161","BK1574","LU0196878994.USD","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642746717","title":"和铂医药-B(02142)：全人源超长效靶向TSLP抗体HBM9378/WIN378治疗COPD的II期 SIRIUS研究已完成首批患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2642746717","media":"智通财经网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642746717?lang=zh_cn&edition=full","pubTime":"2026-06-09 20:15","pubTimestamp":1781007333,"startTime":"0","endTime":"0","summary":"和铂医药-B(02142)发布公告，公司的合作伙伴Windward Bio AG(Windward \nBio)已在HBM9378/WIN378(亦称SKB378，一款全人源超长效靶向胸腺基质淋巴细胞生成素(TSLP)抗体)治疗慢性阻塞性肺疾病(COPD)的II期 \nSIRIUS研究中完成首批患者给药。","market":"sg","thumbnail":"https://img.zhitongcaijing.com/gonggao/ztcj_announce_19.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/gonggao/ztcj_announce_19.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1452176.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1161","02142","BK1574","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104190712","title":"和铂医药-B更新5月股份变动月报表，股本净增662,000股","url":"https://stock-news.laohu8.com/highlight/detail?id=1104190712","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1104190712?lang=zh_cn&edition=full","pubTime":"2026-06-04 22:47","pubTimestamp":1780584425,"startTime":"0","endTime":"0","summary":"2026年6月4日，和铂医药控股有限公司发布截至2026年5月31日的股份变动月报。公告显示，公司注册股本维持在20,000,000,000股，每股面值0.000025美元，注册股本总额500,000美元，与上月保持一致。报告期内，公司已发行股份由上月底的872,842,722股减少至867,607,722股，库存股份由25,937,000股增加至31,834,000股。截至月末，公司已发行及库存股份合计899,441,722股，较上月底净增662,000股。购回与库存情况方面，当月累计购回股份5,897,000股，其中406,000股拟注销但截至月末尚未实际注销，其余购回股份转为库存股。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02142"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":0.0869},{"period":"1month","weight":0.2573},{"period":"3month","weight":-0.1064},{"period":"6month","weight":0.0146},{"period":"1year","weight":0.4072},{"period":"ytd","weight":0.0288}],"compareEarnings":[{"period":"1week","weight":0.0163},{"period":"1month","weight":0.0662},{"period":"3month","weight":-0.0391},{"period":"6month","weight":-0.0668},{"period":"1year","weight":-0.0274},{"period":"ytd","weight":-0.026}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"和铂医药控股有限公司是一家主要从事肿瘤免疫学及免疫性疾病领域的创新疗法开发业务的投资控股公司。该公司的产品主要包括巴托利单抗（HBM9161）、HBM9378、HBM7020、TCE Program、普鲁苏拜单抗（HBM4003）以及HBM7022等。该公司产品主要用于治疗全身型重症肌无力（gMG）、慢性阻塞性肺病（COPD）、哮喘、自身免疫疾病、黑色素瘤、结直肠癌以及实体瘤等。该公司通过专有抗体技术平台“Harbour Mice”、“HBICE”、“HBICA”及单克隆B细胞筛选平台提供下一代抗体以及生物解决方案。","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":0.083377},{"month":2,"riseRate":0.333333,"avgChangeRate":0.000026},{"month":3,"riseRate":0.5,"avgChangeRate":0.051559},{"month":4,"riseRate":0.333333,"avgChangeRate":0.009952},{"month":5,"riseRate":0.5,"avgChangeRate":0.016802},{"month":6,"riseRate":0.166667,"avgChangeRate":-0.072876},{"month":7,"riseRate":0.5,"avgChangeRate":0.058344},{"month":8,"riseRate":0.2,"avgChangeRate":0.005624},{"month":9,"riseRate":0.4,"avgChangeRate":-0.065735},{"month":10,"riseRate":0,"avgChangeRate":-0.180686},{"month":11,"riseRate":0.8,"avgChangeRate":0.25789},{"month":12,"riseRate":0.6,"avgChangeRate":0.266929}],"exchange":"SEHK","name":"和铂医药-B","nameEN":"HBM HOLDINGS-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"和铂医药-B(02142)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供和铂医药-B(02142)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"和铂医药-B,02142,和铂医药-B股票,和铂医药-B股票老虎,和铂医药-B股票老虎国际,和铂医药-B行情,和铂医药-B股票行情,和铂医药-B股价,和铂医药-B股市,和铂医药-B股票价格,和铂医药-B股票交易,和铂医药-B股票购买,和铂医药-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"和铂医药-B(02142)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供和铂医药-B(02142)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}